Connecticut 2021 Regular Session Status: In Committee

SB 847 — AN ACT CONCERNING NEWBORN INFANT HEALTH SCREENING.

Last action — MOVED TO FOOT OF CAL., SENATE

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2021 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Bill Text

What changed in the latest version

223 added · 117 removed

223 line(s) added, 117 removed.

→
Previous
Latest
General Assembly Raised Bill No.
Senate General Assembly File No.
847 January Session, 2021 LCO No.
215 January Session, 2021 Substitute Senate Bill No.
2920 Referred to Committee on PUBLIC HEALTH Introduced by:
847 Senate, March 30, 2021 The Committee on Public Health reported through SEN.
(PH) AN ACT CONCERNING NEWBORN INFANT HEALTH SCREENING.
DAUGHERTY ABRAMS of the 13th Dist., Chairperson of the Committee on the part of the Senate, that the substitute bill ought to pass.
AN ACT CONCERNING NEWBORN INFANT HEALTH SCREENING.
(a) The administrative officer or other person in charge of each institution caring for newborn infants shall cause to have administered to every such newborn infant in its care an HIV-related test, as defined in section 19a-581, a test for [phenylketonuria and other metabolic diseases] amino acid disorders,including phenylketonuria,organicacid disorders, fatty acid oxidation disorders, including, but not limited to, long-chain 3-hydroxyacyl CoA dehydrogenase (L-CHAD) and medium-chain acyl-CoA dehydrogenase (MCAD), hypothyroidism, galactosemia, sickle cell disease, maple syrup urine disease, homocystinuria, biotinidase deficiency, congenital adrenal hyperplasia, severe combined immunodeficiency disease, adrenoleukodystrophy and such other tests for [inborn errors of metabolism] other metabolic and genetic disorders included on the recommended uniform screening panel pursuant to 42 USC 300b-10, as amended from time to time, as LCO No.
(a) The administrative officer or other person in charge of each institution caring for newborn infants, or a nurse-midwife licensed pursuant to chapter 377 or midwife shall cause to have administered to every such newborn infant in its care an HIV-related test, as defined in section 19a-581, a test for [phenylketonuria and other metabolic diseases] amino acid disorders,including phenylketonuria,organicacid disorders, fatty acid oxidation disorders, including, but not limited to, long-chain 3-hydroxyacyl CoA dehydrogenase (L-CHAD) and medium-chain acyl-CoA dehydrogenase (MCAD), hypothyroidism, galactosemia, sickle cell disease, maple syrup urine disease, homocystinuria, biotinidase deficiency, congenital adrenal hyperplasia, severe combined immunodeficiency disease, adrenoleukodystrophy sSB847 / File No.
2920 1 of 4 Raised Bill No.847 [shall be] prescribed by the [Department] Commissioner of Public Health, [.
215 1 sSB847 File No.
The tests shall be administered as soon after birth as is medically appropriate] and subject to the approval of the Secretary of the Office of Policy and Management.
215 and such other tests for [inborn errors of metabolism as shall be] other metabolic and genetic disorders included on the recommended uniform screening panel pursuant to 42 USC 300b-10, as amended from time to time, asprescribed by the [Department]Commissioner ofPublicHealth.
(b) The testing requirements prescribed in subsection (a) of this section shall be performed using a blood spot specimen.
[The tests shall be administered as soon after birth as is medically appropriate.] (b) The testing requirements prescribed in subsection (a) of this section shall be performed using a blood spot specimen.
The blood spot specimen shall be collected no earlier than twenty-four hours after the birth of the newborn infant and not later than forty-eight hours after the birth of such infant, unless the institution determines that a situation exists to warrant an early collection of the specimen or if collection of the specimen is medically contraindicated.
The blood spot specimen shall be collected not earlier than twenty-four hours after the birth of the newborn infant and not later than forty-eight hours after the birth of such infant, unless the institution caring for newborn infants, nurse-midwife licensed pursuant to chapter 377 or midwife determines that a situation exists to warrant an early collection of the specimen or if collection of the specimen is medically contraindicated.
Situations that warrant early collection of the specimen shall include, but shall not be limited to, the imminent transfusion of blood products, dialysis, early discharge of the newborn infant, transfer of the newborn infant to another institution, or imminentdeath.Ifthenewborninfantdiesbeforeabloodspotspecimen can be obtained, the specimen shall be collected as soon as practicable after death.
Situations that warrant early collection of the specimen shall include, but shall not be limited to, the imminent transfusion of blood products, dialysis, early discharge of the newborn infant from the institution, transfer of the newborninfant to another institutionor imminent death.Ifthenewborn infant dies before a blood spot specimen can be obtained, the specimen shall be collected as soon as practicable after death.
The institution licensed to care for newborn infants, or a licensed nurse-midwife or midwife, shall notify the Department of Public Health when a specimen is not collected within forty-eight hours of birth due to medical fragility, refusal by the parents when newborn infant screening is in conflict with their religious tenets and practice, when a newborn infant is receiving comfort measures only, or for any other reason.
The institution licensed to care for newborn infants, nurse-midwife or midwife shall notify theDepartmentofPublicHealth when aspecimen is not collected within forty-eight hours after the birth of such infant due to:
(1) The infant'smedicalfragility,(2)refusalbytheparentswhennewborninfant screening is in conflict with their religious tenets and practice, (3) the newborn infant receiving comfort measures only, or (4) any other reason.
The institution caring for newborn infants or the nurse-midwife or midwife shall send the blood spot specimen to the state public health laboratory not later than twenty-four hours after the time of collection.
The institution caring for newborn infants, nurse-midwife or midwife shall send the blood spot specimen to the state public health laboratory not later than twenty-four hours after the time ofcollection.The department may request anadditionalbloodspot specimen if:
The department may request an additional blood spot specimen if there was an early collection of the specimen or if the specimen was collected following a transfusion of blood products, if the specimen is unsatisfactory for testing or if the department determines that there is an abnormal result.
(A) There was an early collection of the specimen, (B) the sSB847 / File No.
If the mother has had an HIV-related LCO No.
215 2 sSB847 File No.
2920 2 of 4 Raised Bill No.847 test pursuant to section 19a-90 or 19a-593, the person responsible for testing under this section may omit an HIV-related test.
215 specimen was collected following a transfusion of blood products, (C) the specimen is unsatisfactory for testing, or (D) the department determines that there is an abnormal result.
If the mother has had an HIV-related test pursuant to section 19a-90 or 19a-593, the person responsible for testing under this section may omit an HIV-related test.
The administrative officer or other person in charge of each institution caring for newborn infants who performs the testing for critical congenital heart disease shall enter the results of such test into the newborn screening system pursuant to section 19a-53.
The administrative officer or other person in charge of each institution caring for newborn sSB847 / File No.
The administrative officer or other person in LCO No.
215 3 sSB847 File No.
2920 3 of 4 Raised Bill No.
215 infants who performs the testing for critical congenital heart disease shall enter the results of such test into the newborn screening system pursuant to section 19a-53.
847 charge of each institution who performs the testing for cystic fibrosis shall report the number of newborn infants screened and the aggregate results of such testing on an annual basis to the Department of Public Health, in a form and manner prescribed by the Commissioner of Public Health.
The administrative officer or other person in charge of each institution who performs the testing for cystic fibrosis shall report the number of newborn infants screened and the aggregate results of such testing on an annual basis to the Department of Public Health, in a form and manner prescribed by the Commissioner of Public Health.
The provisions of this section shall apply irrespective of the patient's insurance status or source of payment, including self-pay status.
The provisions of this subsection shall apply irrespective of the patient's insurance status or source of payment, including self-pay status.
Section 1 October 1, 2021 19a-55 Statement of Purpose:
Section 1 October 1, 2021 19a-55 Statement of Legislative Commissioners:
To require health screening of newborn infants no earlier than twenty- four hours after the birth of the newborn infant and not later than forty- eight hours after the birth of such infant, and to add various metabolic and genetic disorders to the newborn infant screening panel.
In Subsec.
[Proposed deletions are enclosed in brackets.
(a), "nurse-midwife" was changed to "or a nurse-midwife" for clarity, in Subsec.
Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.] LCO No.
(b) provisions were rewritten and subdivision and subparagraph indicators were added for clarity, and in Subsec.
2920 4 of 4
(d) "section" was changed to "subsection" for accuracy.
PH Joint Favorable Subst.
sSB847 / File No.
215 4 sSB847 File No.
215 The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose.
In general, fiscal impacts are based upon a variety of informational sources, including the analyst’s professional knowledge.
Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.
OFA Fiscal Note State Impact:
None Municipal Impact:
None Explanation The bill, which makes various changes to requirements of health care institutions and the state’s newborn screening program, is not anticipated to result in a fiscal impact to the state or municipalities.
The Out Years State Impact:
None Municipal Impact:
None sSB847 / File No.
Show all 79 changed rows (39 more)
Previous
Latest
215 5 sSB847 File No.
215 OLR Bill Analysis sSB 847 AN ACT CONCERNING NEWBORN INFANT HEALTH SCREENING.
SUMMARY This bill makes various changes to the state’s Newborn Screening Program.
Principally, it:
1.
extends health care institutions’ newborn screening requirements to licensed nurse-midwives and midwives;
2.
requires health care institutions, nurse-midwives, and midwives (hereafter “providers”) to generally perform newborn screenings for genetic and metabolic disorders using blood spot specimens between 24 and 48 hours after birth;
3.
requires providers to send the blood spot specimens to the state public health lab within 24 hours after collection;
4.
requires providers to notify the Department of Public Health (DPH) within 72 hours after a newborn’s birth about the reason why a specimen was not collected in this timeframe, when applicable;
and 5.
eliminates the requirement that the Office of Policy and Management approve a disorder included on the federal Recommended Uniform Screening Panel (RUSP) (see (BACKGROUND) before DPH adds it to the list of conditions for which the program screens.
SeparatefromtheNewbornScreeningProgram,existinglawrequires health care institutions to test newborns for other specified conditions.
The bill eliminates the requirement that institutions test newborns for spinal muscular atrophy but continues to require that they test for sSB847 / File No.
215 6 sSB847 File No.
215 critical congenital heart disease;
cystic fibrosis;
and, when a newborn fails a hearing test, cytomegalovirus.
(The latter must be performed within available appropriations.) It also extends these testing requirements to licensed nurse-midwives and midwives, who must, as under existing law, administer the testing as soon as it is medically appropriate unless the parents object on religious grounds.
Additionally, the bill requires health care institutions that perform the newborn screening test for cystic fibrosis to annually report to DPH the number and aggregate results of the screenings, regardless of the patient’s insurance status or payment source.
Lastly, the bill makes several technical and conforming changes.
EFFECTIVE DATE:
October 1, 2021 NEWBORN SCREENING PROGRAM Testing Timeframes The bill requires providers to perform required newborn screenings using a blood spot specimen.
The specimen must be collected between and 48 hours after the infant’s birth unless the provider determines a situation exists that warrants its early collection or that it is medically contraindicated.
Under the bill, conditions that warrant early collection of the specimen include (1) imminent transfusion of blood products, (2) dialysis, (3) the infant’s early discharge from a health care institution or transfer from one institution to another, or (4) imminent death.
Under the bill, if a newborn dies before a blood spot specimen is obtained, then the specimen must be collected as soon as practicable after death.
Notification Requirements The bill requires providers to notify DPH when a specimen is not collected within the required 48 hours after birth for any reason, including (1) medical fragility, (2) the parent’s refusal of the screening sSB847 / File No.
215 7 sSB847 File No.
215 due to religious conflict, or (3) a newborn receiving comfort measures only.
Under the bill, providers must document the reason in the state’s newborn screening system or send written notification to DPH within hours after the newborn’s birth.
Specimen Processing The bill requires providers to send the blood spot specimen to the state’s public health laboratory within 24 hours after collecting it.
DPH may request an additional blood spot specimen if the specimen (1) was collected early or after a blood transfusion, (2) is unsatisfactory for testing, or (3) yields an abnormal result as determined by the department.
BACKGROUND Recommended Uniform Screening Panel RUSP is a list of health conditions that the federal Department of Health and Human Services recommends states screen for as part of their newborn screening programs.
Conditions are included on the list based on evidence of the potential benefit of screening, states’ ability to screen, and the availability of effective treatments (42 U.S.C.
§ 300b-10).
COMMITTEE ACTION Public Health Committee Joint Favorable Substitute Yea 32 Nay 1 (03/12/2021) sSB847 / File No.
215 8
⬇ Download PDF
View plain text versions (3)

Action History

  1. MOVED TO FOOT OF CAL., SENATE

  2. FILE NO. 215

  3. SENATE CALENDAR NUMBER 170

  4. FAV. RPT., TAB. FOR CAL., SEN.

  5. RPTD. OUT OF LCO

  6. REFERRED TO Office of Legislative Research AND Office of Fiscal Analysis 03/29/21

  7. FILED WITH LCO

  8. Joint Favorable Substitute

  9. PUBLIC HEARING 0303

  10. REF. TO JOINT COMM. ON Public Health

Sponsors

  • William A. Petit · Primary

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 186 not signed on

Sponsors (1)

  • Petit, William A.

Co-sponsors (0)

None.

Not signed on (186)

186 members have not signed on to this bill.

Show all 186 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors SB 847?
SB 847 is sponsored by Petit, William A..
What is the current status of SB 847?
This bill died with 2021 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track SB 847?
Track SB 847 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 847

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 847

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →